SHIFT Newsroom · UK
Retatrutide fakes: a research headline is not a treatment offer
Why impressive packaging cannot replace medicine authorisation, prescription checks and a verified pharmacy.
The Times reported on fake retatrutide on 10 October 2026. Retatrutide remains investigational, not a UK-authorised commercial treatment.
The MHRA’s existing July warning says products sold as retatrutide may not contain it, with no assurance of safety, quality or effectiveness. Its May raid is earlier enforcement context, not a new October incident.
SHIFT’s take
We won’t turn research news into a checkout. Promising trials, UK authorisation and verified pharmacy supply are different steps. Where SHIFT cannot supply a treatment, we’ll say so.
For members: check the pharmacy’s registration and expect a prescriber assessment. An offer without a prescription is a warning sign. If unsure, check or report a suspicious medicine seller. Our reporting is information, not an offer of retatrutide.
Known facts
- The MHRA’s 24 July 2026 warning says retatrutide is not authorised for use in the UK.